Controlling each cell inside the body to deliver cures.

Deliver Biosciences is building a nanoparticle-based delivery platform to genetically engineer cells inside patients to create scalable, affordable and potent cell and gene therapies.

About

thumb

Our nanoparticle delivery vectors can be customised and can transport a diverse set of payloads safely and efficiently  to cells of choice in patients.

The ability to effectively target and reprogramme cells in vivo will unlock the full potential of many technologies including CRISPR, and other gene editing tools.

Our first product is for cancer immunotherapies. Long term, this technology could be used for developing therapies for serious indications  such as autoimmune (e.g. diabetes, arthritis), neurodegenerative (e.g. Alzheimer’s and multiple sclerosis)  and cardiovascular diseases that don’t have curative treatments.

Our Team

Our team includes driven and passionate scientists and experts in cell and molecular biology, chemistry, nanotechnology, and cell/gene therapy from several research institutions including the University of Cambridge, Imperial College London, University College London, Stanford University and King’s College London.

thumb

Dr. Bakul Gupta

CEO and Co-Founder

Dr. Bakul Gupta

CEO and Co-Founder

Bakul is the co-founder and CEO of Deliver Biosciences. Bakul’s technical knowledge in biomaterials, nanomaterials and chemistry has laid the foundation of Deliver Bio’s technology enabling us to explore in vivo cell therapy. Bakul has participated in various entrepreneurial programmes during her PhD and postdoc, and has won several awards for her work. The most recent ones include her mention as the Top 5 biotech entrepreneurs of Asian origin, and has also been recognised as one of the top 30 entrepreneurs in UK life sciences and healthcare. Growing up in a family of clinicians and participating in entrepreneurial programmes, Bakul has learnt the value healthcare brings to communities and is passionate about using her experience to build a product which improves patients’ lives. Bakul completed her PhD from UNSW Australia followed by a GSK-funded Postdoctoral fellowship at Imperial College London.
thumb

Dr. George Tetley

CSO and Co-Founder

Dr. George Tetley

CSO and Co-Founder

George is the co-founder and CSO of Deliver Biosciences. He has a broad bioscience background, covering immunology and biochemistry and cancer drug discovery. George has co-conceived the idea behind Deliver’s technology with his co-founder Bakul. During this PhD and subsequent postdoc he discovered and developed peptide inhibitors for intracellular proteins involved in cancerous signal dysregulation. The peptide compounds produced during his PhD have been pursued in a collaboration with MedImmune/Astra Zeneca. George is a gold medalist and topped Biochemistry and Immunology during his under-graduation at Trinity College Dublin. He completed his PhD and Postdoctoral work at the University of Cambridge, and has an online MBA from Quantic School of Business and Technology.
thumb

Dr. Lucas Harrington

Advisor

icon

Dr. Lucas Harrington

Advisor

Lucas Harrington is a co-founder and Chief Scientific Officer of Mammoth Biosciences. He is also a partner at SciFounders, a San Francisco based venture capital fund, aimed at backing technical founders to start science heavy companies. He holds a PhD in Biochemistry from the University of California Berkeley and worked in the lab of Nobel Laureate Jennifer Doudna, who is also a co-founder for Mammoth Biosciences.
thumb

Dr. Scott Dylla

Advisor

icon

Dr. Scott Dylla

Advisor

He was the co-founder and chief scientific officer of Stemcentrx, which was acquired by AbbVie in 2016. Scott trained as a postdoctoral scholar at Stanford University in the laboratory of Dr. Irving L. Weissman, where he was awarded American Cancer Society and Stanford Immunology fellowships, and was subsequently a Sr. Scientist at OncoMed Pharmaceuticals. In 2005, Scott was recognized by the British Council as one of eight outstanding young US-based researchers in the field of stem cell biology.
thumb

Dr. Martin Pule

Advisor

icon

Dr. Martin Pule

Advisor

Martin Pule is a Clinical Senior Lecturer in the department of Haematology at University College London’s Cancer Institute and also serves as an Honorary Consultant in Haematology at University College London Hospital. His research is focused on many aspects of genetic engineering of T-cells for cancer treatment, with a particular focus on CARs. He is the founder of a UK-based biotech, Autolus, which is working on developing novel CAR-T therapies for patients with blood cancers. He holds a Bachelor of Medicine and Bachelor of Surgery from University College Dublin and is a Fellow of the Royal College of Pathologists.

Science

thumb

We have developed a targeted nanoparticle system which delivers diverse payloads including DNA, and mRNA.

Our nanoparticles have been designed to avoid accumulation in off-target organs such as  the liver, and to deliver the payloads efficiently to the desired cells in the body.

Our first product targets T-cells and delivers a chimeric antigen receptor (CAR) gene, to turn them into tumour killing CAR-T cells. Our product will be easier to administer, will not require specialised manufacturing centres that come with long and expensive supply chains, reaching more patients.

Our nanoparticle technology is easy to load, mass-produce, and equipped with programmable targeting domains allowing us to modify many different cell types, such as stem cells, neurons, and heart cells, addressing many indications in the future.

thumb
thumb

Partner with Deliver

We are developing a versatile nanoparticle platform for this purpose, which we can specifically target to cells of choice. We are always open to partnering with companies and institutions with complementary expertise or technologies to facilitate in vivo delivery and speed up clinical development. We are actively seeking collaborations where delivering multiple payloads to specific cells is highly desirable in achieving a particular therapeutic effect.